Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HISTORI
2020-004374-22Phase 2Completed
- Sponsor
- Steno Diabetes Center Odense
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prediabetes, cardiometabolic risk (CMR) and schizophrenia comparing Ozempic with Placebo (2 arms). Primary endpoints: Change in HbA1c at 3 months and Change in HbA1c at 6 months. Started Nov 2020; status: completed.
02
Drugs
03
Conditions
prediabetescardiometabolic risk (CMR)schizophrenia
Beyond the preview
Go deeper on 2020-004374-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004374-22.